GHK-Cu for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

GHK-Cu for Health & Longevity

Created on 08/10/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A copper-carrying peptide the body makes itself, most plentiful where tissue is being repaired and lower with age. Laboratory and animal work shows it builds skin structure and calms inflammation; human testing has not kept pace. Creams carry modest risks: irritation, temporary staining, poor mixing with acidic products. Injected and online-sold material is unapproved and made without manufacturing oversight. (Full Review)

Protocol

Standard topical protocol as used by clinicians and formulators
1–3 mg/mL (0.1–0.3%)
Leave-on serum or cream on cleansed skin, once or twice daily, neutral-pH vehicle, indefinitely
Post-procedural protocol
Start 24–72 h after, for 2–4 weeks
Once the wound surface has sealed after microneedling, laser, peeling or surgery; once or twice daily
Competing approach — systemic injectable use
1–2 mg daily, 20–30 day cycles
Subcutaneous; no clinical trial at any dose, parameters from practitioner convention and vendor guidance
Time to effect
Skin texture and hydration
4–6 weeks
Typically reported window for the first cosmetic change
Fine lines and firmness
8–12 weeks
At the earliest; assessment before eight weeks assesses the vehicle
Wound healing
Days
The ongoing controlled study assesses re-epithelialization over 21 days

Benefits

Contraindications
  • Copper chelating drugs (penicillamine, trientine, tetrathiomolybdate)
  • Wilson disease and other copper transport disorders, any dose or route
  • Cholestatic liver disease or cirrhosis, Child-Pugh Class B or C
  • Chronic kidney disease stage 4 or beyond (below 30 mL/min/1.73 m²)
  • Active malignancy, or treated within 12 months
  • Pregnancy and lactation
  • Known copper or peptide contact allergy
  • Keloid or hypertrophic scarring tendency (topical use on healing wounds)
  • Injectable use (unapproved, sterility unverified)
    •
Key Interactions
  • Oral copper supplements and copper-containing multivitamins (gluconate, bisglycinate, sulfate)
  • High-dose zinc (above 40 mg/day elemental)
  • Molybdenum supplements; vitamin C above 1,000 mg/day
  • Oral iron supplements
  • Topical vitamin C, alpha-hydroxy acids (glycolic, lactic), beta-hydroxy acids (salicylic), benzoyl peroxide
  • Topical retinoids (retinol, adapalene, tretinoin)
  • Systemic corticosteroids (prednisone), immunosuppressants (ciclosporin, tacrolimus), cytotoxic chemotherapy (methotrexate)
  • Other peptides in common stacks (BPC-157, thymosin beta-4, ipamorelin, CJC-1295)
    •

Risk & Side Effects

  • High: Product quality failure in gray-market and research-grade material
  • Medium: Local skin reactions: irritation, erythema and contact dermatitis; injection-site reactions and systemic copper load with injectable use; absence of long-term human safety data at any systemic dose
  • Low: Copper accumulation in people with impaired copper clearance; chemical incompatibility with other topical actives; transient blue-green staining and cosmetic discoloration
  • Speculative: Promotion of growth in occult tumors; copper-driven oxidative injury and cuproptosis at high local concentrations; excessive matrix deposition and scarring

Monitoring

Marker Target Why
Serum copper (total) 80–110 µg/dL Detects copper excess or insufficiency during systemic use
Ceruloplasmin 20–30 mg/dL The main copper-carrying protein; a low value alongside high total copper points to impaired handling
Non-ceruloplasmin-bound copper Below 10 µg/dL The fraction most associated with copper-driven oxidative injury
Serum zinc 90–120 µg/dL Copper and zinc compete for absorption, so one cannot be interpreted without the other
Copper-to-zinc ratio 0.7–1.0 A rising ratio tracks inflammation and predicts adverse outcomes in older adults
hs-CRP Below 1.0 mg/L Distinguishes a raised copper value caused by inflammation from one caused by intake
ALT and AST ALT below 25 U/L in men and below 20 U/L in women; AST below 25 U/L The liver excretes copper into bile, so hepatic injury raises retention risk
Complete blood count Hemoglobin and neutrophil count within the reference interval Copper imbalance in either direction shows up first in red cells and neutrophils
24-hour urinary copper Below 40 µg/24 h Confirms suspected copper overload when serum results are ambiguous

Cadence: Systemic use — copper panel and liver enzymes at 8–12 weeks, then every 6–12 months, with an unscheduled repeat at any symptom of copper excess. Topical use — no laboratory cadence; standardized photography at baseline, 4, 8 and 12 weeks.

Qualitative Assessment

  • Skin texture and smoothness by touch and close-up photography, the first domain to change
  • Skin firmness and recoil at the cheek and jawline, changing later than texture
  • Wound and procedure recovery time compared against previous procedures of the same type
  • Redness, stinging or dryness in the first two weeks, distinguishing adaptation from intolerance
  • Scalp shedding and hair density where a scalp preparation is used, by standardized part-line photography
  • Energy, appetite and right upper quadrant comfort during systemic use, when symptoms are non-specific
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.